Correlation between plasma transforming growth factor-beta 1 and second primary breast cancer in a chemoprevention trial.
The relationship between plasma transforming growth factor-beta 1 (TGF-beta 1) and second primary breast cancer was explored in a prevention trial of the synthetic retinoid fenretinide (N-(4-hydroxyphenyl)retinamide; 4-HPR). Plasma concentrations of TGF-beta 1 were measured by radioimmunoassay in plasma obtained at randomisation and after approximately 1 year of intervention in 28 women treated with 4-HPR and 27 untreated controls with stage I breast cancer. Baseline and 1 year growth factor concentrations were not significantly different between treated and control groups. After a median follow-up of 65 months, an increase in TGF-beta 1 over 1 year was the only significant, independent predictor of a shorter survival free from secondary primary breast cancer. Moreover, the change in TGF-beta 1 levels had a tendency to influence the treatment effect on second breast cancer incidence. Our data suggest that the role of plasma TGF-beta 1 as a surrogate endpoint of breast carcinogenesis should be assessed further.
Decensi
A
A
FIRC Chemoprevention Unit, European Institute of Oncology, Milan, Italy.
Torrisi
R
R
Fontana
V
V
Barreca
A
A
Ponzani
P
P
Pensa
F
F
Parodi
S
S
Costa
A
A
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000097:blood* / Q000517:prevention & control; D018572:Disease-Free Survival; D005260:Female; D017313:Fenretinide / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000097:blood* / Q000517:prevention & control; D011863:Radioimmunoassay / Q000379:methods; D016212:Transforming Growth Factor beta / Q000097:blood*
D000970:Antineoplastic Agents; D016212:Transforming Growth Factor beta; D017313:Fenretinide